Pregnancy Plans and Birth Control on a Telehealth GLP-1: What Labels Say
If you could become pregnant and you are getting a GLP-1 online, the labels give your prescriber specific things to tell you. Semaglutide (Wegovy, Ozempic) should be stopped at least 2 months before a planned pregnancy, and tirzepatide (Zepbound, Mounjaro) and Foundayo can make birth control pills less reliable for set periods after you start and after each dose increase. A platform that never asks about pregnancy plans or contraception is skipping part of the label.
Key takeaways
- The Wegovy and Ozempic labels say to stop semaglutide at least 2 months before a planned pregnancy because it stays in the body for weeks.
- Zepbound and Mounjaro labels say oral hormonal birth control may be less effective: switch to a non-oral method, or add a barrier method for 4 weeks after starting and 4 weeks after each dose increase.
- Foundayo's label uses a 30-day backup window and advises effective contraception during treatment.
- If you become pregnant while on a weight-loss GLP-1, the labels say to stop it once pregnancy is recognized. Contact your prescriber and your OB or primary care clinician.
- Manufacturer pregnancy exposure registries exist, and labels encourage pregnant patients to enroll.
Why the labels treat pregnancy so carefully
Every weight-loss GLP-1 label in this guide uses similar language: weight loss offers no benefit to a pregnant patient and may cause fetal harm. That line appears in the Zepbound prescribing information and the Foundayo prescribing information, and the Saxenda label likewise says to discontinue when pregnancy is recognized.
There are two separate issues for a telehealth patient. The first is timing: how long before trying to conceive should you stop? The second is contraception: some of these drugs can interfere with birth control pills, which raises the chance of an unplanned pregnancy in the first place. Your prescriber should cover both, and the intake form is where you can tell whether they intend to.
Planning a pregnancy: the 2-month rule for semaglutide
The Wegovy label (revised June 2026), which now covers both the injection and the Wegovy pill, tells prescribers to discontinue Wegovy "at least 2 months before they plan to become pregnant," citing semaglutide's long half-life. The Ozempic label (revised May 2026) carries a matching instruction, again pointing to the long washout period.
The tirzepatide and orforglipron labels are worded differently. The Zepbound and Foundayo labels say to discontinue when a pregnancy is recognized, and the Foundayo label asks patients to tell their provider if they are pregnant or intend to become pregnant. The Mounjaro label, written for type 2 diabetes, says use in pregnancy should happen only if the potential benefit justifies the potential risk to the fetus. That difference reflects the condition being treated: blood sugar control during pregnancy is a medical need, while weight loss is not.
If you are planning a pregnancy in the next year, tell your telehealth prescriber now. A timeline that includes stopping, a washout period and a conversation with an OB or primary care clinician is easier to build in advance than after a positive test.
Birth control: which labels require a change
GLP-1 drugs slow stomach emptying, which can change how well some pills are absorbed. For birth control, the labels do not all say the same thing.
| Product | What the label says about birth control pills | Planned-pregnancy instruction |
|---|---|---|
| Zepbound (tirzepatide) | Switch to a non-oral method, or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase | Discontinue when pregnancy is recognized |
| Mounjaro (tirzepatide) | Same 4-week rule as Zepbound | Use in pregnancy only if benefit justifies risk |
| Foundayo (orforglipron) | Switch to a non-oral method, or add a barrier method for 30 days after starting and for 30 days after each dose increase; use effective contraception during treatment | Discontinue when pregnancy is recognized |
| Wegovy (injection and pill) | No switch or backup instruction; a study found no clinically significant change in ethinyl estradiol or levonorgestrel levels | Stop at least 2 months before a planned pregnancy |
| Ozempic | No switch or backup instruction; its interaction study found no dose adjustment needed for ethinyl estradiol/levonorgestrel | Stop at least 2 months before a planned pregnancy |
Source: prescribing information for Zepbound (rev. 8/2026), Mounjaro (rev. 8/2026), Foundayo (rev. 7/2026), Wegovy (rev. 6/2026) and Ozempic (rev. 5/2026).
The tirzepatide rule is worth reading carefully. The Zepbound label says:
Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method
It then offers the alternative of adding a barrier method for 4 weeks after starting and 4 weeks after each dose escalation. The label adds that non-oral hormonal methods are not expected to be affected. On a typical tirzepatide titration with several step-ups, those 4-week windows can add up to a large share of your first months on treatment.
Foundayo, Lilly's daily GLP-1 pill, uses 30-day windows instead of 4 weeks. Its label also includes a broader line: "Advise women of childbearing potential to use effective contraception during treatment with FOUNDAYO."
Comparing telehealth GLP-1 programs?
Look at how each one screens for pregnancy plans and contraception, and verify licensing and terms directly with the provider.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
If you become pregnant while on treatment
Unplanned pregnancies happen, including while on these drugs. The labels for Zepbound, Foundayo, Saxenda and Wegovy (for weight reduction) say to discontinue the drug when pregnancy is recognized. A practical sequence:
- Do not take your next scheduled dose until you have spoken with a clinician.
- Message your telehealth prescriber with the date of your positive test, your last dose date and current dose.
- Contact your OB, midwife or primary care clinician and tell them which GLP-1 you were taking and for how long. They manage the pregnancy, not the weight program.
- Pause any auto-ship so you are not billed for medication you have been told to stop.
- Consider the pregnancy exposure registry for your drug (details below).
Pregnancy exposure registries
Registries collect outcomes for people exposed to a drug during pregnancy, which is how evidence on safety builds over time. The labels list these contacts:
- Wegovy: Novo Nordisk at 1-877-390-2760 or wegovypregnancyregistry.com, per the Wegovy label.
- Zepbound: 1-844-524-0039 or MILEregistry@thermofisher.com, per the Zepbound label.
- Foundayo: the label lists Eli Lilly at 1-800-LillyRx (1-800-545-5979) for its pregnancy exposure registry.
Breastfeeding after delivery
Postpartum weight is a common reason people come back to telehealth programs, so lactation matters too. The labels again differ. The Wegovy label says breastfeeding is not recommended during treatment with Wegovy tablets, and gives separate guidance for the injection. The Foundayo label says it is not recommended for nursing women. The Zepbound label reports that in a single-dose study of 11 lactating women, tirzepatide was undetectable or low in breast milk, with no data on effects on infants, and asks clinicians to weigh benefits and risks. If you are breastfeeding, say so on intake every time, even if the form doesn't ask.
Intake questions that show a platform is screening properly
You can learn a lot about a telehealth program from its intake. A form that takes this seriously will ask some version of these:
- Are you currently pregnant, or could you be?
- Are you planning to become pregnant in the next several months?
- Are you breastfeeding?
- What form of contraception do you use, if any? (Oral, IUD, implant, injection, patch, ring, barrier, none.)
- Consent or acknowledgment that you will report a pregnancy and stop the drug.
| Question to check | Why it matters | What to do |
|---|---|---|
| Does the intake ask about pregnancy plans? | Semaglutide labels require stopping at least 2 months ahead | If not asked, volunteer your plans in a message and keep the reply |
| Does it ask your contraception type? | Tirzepatide and Foundayo labels affect oral methods | If you use an oral method, ask how long backup is needed after each dose change |
| Does the prescriber mention backup after dose increases, not only at the start? | The windows restart with each escalation | Put the windows on your calendar when a new dose ships |
| Is there a clear way to report a pregnancy and pause shipments? | Labels say to discontinue once pregnancy is recognized | Find the pause and messaging options before you need them |
Source: label sections 7, 8.1, 8.2 and 8.3 of the products listed above.
Hypothetical scenarios
These are illustrations, not real patients.
Hypothetical A: You use a combined birth control pill and start Zepbound through an online program. The intake asked about contraception, and the prescriber's welcome message explains the 4-week backup rule. Each time your dose steps up, a new 4-week window starts. This is a platform following the label.
Hypothetical B: You are on compounded semaglutide and hoping to conceive next spring. The intake never asked. Here you raise it yourself, ask your prescriber how the 2-month washout in the Wegovy and Ozempic labels applies to your product, and loop in your OB. The FDA notes that compounded drugs are not FDA approved, so there is no compounded-specific label to point to; the brand labels are the closest reference.
Where this guide stops
This page summarizes what FDA labels say as of October 2026. It cannot choose a contraceptive method for you, tell you when to stop a medication, or assess a pregnancy. Those decisions need your prescriber and a clinician who handles reproductive care.
Weighing your telehealth options?
Compare participating providers, then confirm their licensing, pharmacy and screening process directly before you enroll.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
How long before trying to get pregnant should I stop Wegovy or Ozempic?
The Wegovy and Ozempic labels say to discontinue at least 2 months before a planned pregnancy because semaglutide has a long washout period. Talk to your prescriber and your OB or primary care clinician about timing.
Does Zepbound make birth control pills less effective?
The Zepbound and Mounjaro labels say oral hormonal contraceptives may be affected. They advise switching to a non-oral method, or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.
What does the Foundayo label say about contraception?
It advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase, and says women of childbearing potential should use effective contraception during treatment.
What should I do if I get pregnant while taking a GLP-1 for weight loss?
The weight-loss labels say to discontinue once pregnancy is recognized. Contact your telehealth prescriber and your OB or primary care clinician, pause any auto-ship, and consider the manufacturer's pregnancy exposure registry.
Sources
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (revised June 2026)
- Ozempic prescribing information, Novo Nordisk (revised May 2026)
- Zepbound prescribing information, Eli Lilly (revised August 2026)
- Mounjaro prescribing information, Eli Lilly (revised August 2026)
- Foundayo (orforglipron) prescribing information, Eli Lilly (revised July 2026)
- Saxenda prescribing information, Novo Nordisk (revised February 2026)
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.